CoChat

A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech

Open access
Josephs, Keith A., Duffy, Joseph R., Clark, Heather M., Utianski, Rene L., Strand, Edythe A., Machulda, Mary M., Botha, Hugo, Martin, Peter R., Pham, Nha Trang Thu, Stierwalt, Julie, Ali, Farwa, Buciuc, Marina, Baker, Matthew, Fernandez De Castro, Cristhoper H., Spychalla, Anthony J., Schwarz, Christopher G., Reid, Robert I., Senjem, Matthew L., Jack, Clifford R., Lowe, Val J., Bigio, Eileen H., Reichard, Ross R., Polley, Eric. J., Ertekin-Taner, Nilufer, Rademakers, Rosa, DeTure, Michael A., Ross, Owen A., Dickson, Dennis W., Whitwell, Jennifer L. · 2021 · Nature Communications
Cited by 70

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Progressive apraxia of speech is a neurodegenerative syndrome affecting spoken communication. Molecular pathology, biochemistry, genetics, and longitudinal imaging were investigated in 32 autopsy-confirmed patients with progressive apraxia of speech who were followed over 10 years. Corticobasal degeneration and progressive supranuclear palsy (4R-tauopathies) were the most common underlying pathologies. Perceptually distinct speech characteristics, combined with age-at-onset, predicted specific 4R-tauopathy; phonetic subtype and younger age predicted corticobasal degeneration, and prosodic subtype and older age predicted progressive supranuclear palsy. Phonetic and prosodic subtypes showed differing relationships within the cortico-striato-pallido-nigro-luysial network. Biochemical analysis revealed no distinct differences in aggregated 4R-tau while tau H1 haplotype frequency (69%) was lower compared to 1000+ autopsy-confirmed 4R-tauopathies. Corticobasal degeneration patients had faster rates of decline, greater cortical degeneration, and shorter illness duration than progressive supranuclear palsy. These findings help define the pathobiology of progressive apraxia of speech and may have consequences for development of 4R-tau targeting treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23687-8

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 70

Metadata

Authors
Josephs, K. A., Duffy, J. R., Clark, H. M., Utianski, R. L., Strand, E. A., Machulda, M. M., Botha, H., Martin, P. R., Pham, N. T. T., Stierwalt, J., Ali, F., Buciuc, M., Baker, M., Fernandez De Castro, C. H., Spychalla, A. J., Schwarz, C. G., Reid, R. I., Senjem, M. L., Jack, C. R., Lowe, V. J., Bigio, E. H., Reichard, R. R., Polley, E. J., Ertekin-Taner, N., Rademakers, R., DeTure, M. A., Ross, O. A., Dickson, D. W., & Whitwell, J. L.
Venue
Nature Communications
Published
2021-06-08
Volume
12
Issue
1
Pages
3452-3452
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3173062894
Cited by
70
References
15
FWCI
7.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. https://app.cochat.ai/papers/10.1038/s41467-021-23687-8
The paper
Josephs, K. A., Duffy, J. R., Clark, H. M., Utianski, R. L., Strand, E. A., Machulda, M. M., Botha, H., Martin, P. R., Pham, N. T. T., Stierwalt, J., Ali, F., Buciuc, M., Baker, M., Fernandez De Castro, C. H., Spychalla, A. J., Schwarz, C. G., Reid, R. I., Senjem, M. L., Jack, C. R., . . . Whitwell, J. L. (2021). A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications. https://doi.org/10.1038/s41467-021-23687-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.